Good question... and very possible. Some assume that since
Good question... and very possible. Some assume that since no JV has been finalized, no one is interested, or the JV partner walked away. The reality is none of us has any idea what is happening in those negotiations.
Since the discussion of the spinoff, and the ICON agreement, I have started considering another option to the JV partnership with large up-front payment.
Based on the recent discussions by management in the business update call, as well as the discussions related to the possibility of entering into a big pharma bidding war over LymPro, I believe there may be a strategy to sell LymPro or even the entire diagnostics division to a BP after the division is spun out to a separate entity and after revenue is ramping up and there are more options using multiple biomarkers in the analysis. The sale of the diagnostics division would certainly be more complicated if a partnership with a big pharma already existed (especially one that wasn't the high bidder for the buyout). Perhaps the company inked the ICON master service agreement to enable them to bring LymPro to market and keep the legal requirements much simpler for the future bidding war/buyout of the diagnostics division.
From the articles cannoli posted last week, a spinoff/buyout is one of the best ways to maximize shareholder value for the assets being sold. Perhaps shareholders should stop relying so much on their expectations of a large up-front payment and look at the overall strategic picture. I am confident this management team is exploring the best option to bring value to the company, even as shareholders whine over unmet expectations.
All those crying over unmet expectations and an inexperienced CEO should remember to include that part in their story when describing what a great investment they made here to their family, friends, and coworkers. Be sure to mention all the bellyaching and sleepless nights that accompanied the savvy investment decision that was made. You certainly wouldn't want to be a hypocrite by claiming you maintained confidence all along as the story unfolded. LOL
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....
Continue Reading
If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...
Continue Reading
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...
Continue Reading
Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...
Continue Reading
A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...
Continue Reading
Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...
Continue Reading
A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...
Continue Reading
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Top 5 Most Recently Viewed Articles
Verona Pharma Achieves Record Stock Price Milestone Verona Pharma PLC (NASDAQ: VRNA) has recently reached a remarkable milestone, with its stock price soaring to an all-time high of $49.05. This achievement highlights the company’s impressive growth trajectory and resilience in the biopharmaceutical sector, particularly in addressing respiratory diseases. Impressive...
Continue Reading
Exciting Developments from the AGM of Foresight Ventures VCT PLC FORESIGHT VENTURES VCT PLC LEI: 213800R88MRC4Y3OIW86 During the recent Annual General Meeting, Foresight Ventures VCT plc showcased a remarkable turnout in terms of shareholder engagement, underscoring the company’s commitment to transparency and active participation in governance. Key Resolutions Passed...
Continue Reading
Diego Lopes Triumphs in a Thrilling TKO Victory at Noche UFC In an electrifying match, Diego Lopes made headlines by defeating Jean Silva at the Noche UFC event. Lopes, a talented 30-year-old Brazilian fighter, displayed exceptional skill and resilience, clinching a TKO victory in the second round of the Featherweight bout. A Historic Night in Mixed Martial Arts This...
Continue Reading
Cryptocurrency Market Analysis In the past year, numerous cryptocurrencies have seen a surge as investors anticipated a decrease in interest rates, prompting a return to speculative investments. Significant events, such as the approval of the first spot price exchange-traded funds (ETFs) for Bitcoin and Ether, Ripple's favorable ruling against the U.S. Securities and...
Continue Reading
Transforming Cloud Carbon Management with GreenOps In a groundbreaking initiative, OxygenIT has introduced its GreenOps platform, providing organizations with a free and comprehensive tool designed to eliminate the guesswork involved in calculating cloud carbon footprints. This innovative approach seeks to empower businesses of any size to replace unreliable manual...
Continue Reading